目的 研究CRLF2过表达的急性B淋巴细胞白血病（B‑cell acute lymphoblastic leukemia, B‑ALL）患儿的临床特征及其预后影响。 方法 回顾性选取2018年10月—2022年10月于四川省妇幼保健院和昆明市儿童医院收治的B‑ALL患儿为研究对象。根据初诊时CRLF2基因检测情况，分为CRLF2过表达组与对照组，比较两组患儿临床特征及预后情况。 结果 共纳入93例B‑ALL患儿，其中CRLF2过表达组29例，对照组64例，发病年龄为2~12岁。CRLF2过表达组在初诊时肝脾大、血小板减少的比例显著低于对照组（P0.05），初诊时出现包块的比例显著高于对照组（P0.05）。CRLF2过表达组的CRLF2蛋白表达量较对照组显著升高（P0.05）。CRLF2过表达组患儿3年平均无事件生存率和总生存率分别为75.9%、85.9%，均低于对照组（90.1%、91.0%），但差异无统计学意义（P0.05）。 结论 CRLF2过表达可能对B-ALL的疾病进展有一定作用，其预后价值需扩大样本量进一步验证。

Objective To study the clinical features and prognostic impact of CRLF2 overexpression in children with B-cell acute lymphoblastic leukemia (B-ALL). Methods A retrospective study included pediatric B-ALL patients admitted to Sichuan Provincial Maternity and Child Health Care Hospital and Kunming Children's Hospital from October 2018 to October 2022. Patients were divided into a CRLF2 overexpression group and a control group without CRLF2 overexpression according to CRLF2 gene testing at initial diagnosis. Clinical features and prognosis between groups were compared. Results A total of 93 children with B-ALL were enrolled, including 29 with CRLF2 overexpression. The age of onset ranged from 2 to 12 years. At diagnosis, the proportions of hepatosplenomegaly and thrombocytopenia in the CRLF2 overexpression group were significantly lower than those in the control group (P0.05), while the proportion of masses was significantly higher (P0.05). Significantly higher CRLF2 protein expression in the CRLF2 overexpression group than in the control group (P0.05). The mean 3-year event-free survival (EFS) and overall survival (OS) rates in the CRLF2 overexpression group were 75.9% and 85.9%, respectively, lower than the control group (90.1% and 91.0%, respectively), but the differences lacked statistical significance by log-rank test. Conclusions These findings suggest a potential role of CRLF2 overexpression in disease progression. Further studies with larger sample sizes are warranted to confirm its prognostic significance.